Since the introduction of Sodium-glucose cotransporter 2 (SGLT2) inhibitors as guideline therapy for both uncontrolled type 2 diabetes mellitus and heart failure, these medications have become popular options as add-on therapy. This class of medication reduces blood glucose levels via inhibition of glucose reabsorption in the proximal convoluted tubules leading to enhanced renal excretion. Not only do SGLT2 inhibitors provide advantages in improved glucose control, but also have proven to reduce cardiovascular mortality. Generally, SGLT2 inhibitors are well tolerated, however adverse reactions of genitourinary tract infections secondary to glucosuria and hypotension from associated osmotic diuresis have been reported. Less commonly, pancreatitis has been associated with use of SGL2 inhibitors. We present a case of suspected empagliflozin induced pancreatitis notable for delayed onset at approximately 120 days since SGLT2 inhibitor initiation.
Identifer | oai:union.ndltd.org:ETSU/oai:dc.etsu.edu:asrf-2104 |
Date | 25 April 2023 |
Creators | Thompson, Jeff, DO, Khattak, Taif, MD, Agarwal, Divya, Slough, Sharlet, DO |
Publisher | Digital Commons @ East Tennessee State University |
Source Sets | East Tennessee State University |
Detected Language | English |
Type | text |
Source | Appalachian Student Research Forum |
Page generated in 0.0015 seconds